Shuttle Pharmaceuticals Files S-1 for Securities Offering
Ticker: SHPH · Form: S-1 · Filed: Jan 15, 2025 · CIK: 1757499
| Field | Detail |
|---|---|
| Company | Shuttle Pharmaceuticals Holdings, Inc. (SHPH) |
| Form Type | S-1 |
| Filed Date | Jan 15, 2025 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $831,579, $469,214, $1.42, $0.8999, $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: S-1, pharmaceutical, securities-offering
TL;DR
Shuttle Pharma is going public, filing S-1 for a securities offering.
AI Summary
Shuttle Pharmaceuticals Holdings, Inc. filed an S-1 form on January 15, 2025, indicating its intention to offer securities. The company, based in Gaithersburg, MD, operates in the pharmaceutical preparations sector. Financial data for periods ending September 30, 2024, and December 31, 2023, are included in the filing.
Why It Matters
This S-1 filing signals Shuttle Pharmaceuticals' move towards raising capital through the public markets, which could fund its research and development or expansion efforts.
Risk Assessment
Risk Level: medium — As a pharmaceutical company filing an S-1, it's likely in an early stage of development or seeking significant funding, which carries inherent risks.
Key Numbers
- 2024-09-30 — Reporting Period End Date (Financial data available up to this date)
- 2023-12-31 — Previous Fiscal Year End (Financial data for the prior year)
Key Players & Entities
- Shuttle Pharmaceuticals Holdings, Inc. (company) — Filer of the S-1
- 20250115 (date) — Filing date
- Gaithersburg, MD (location) — Company's business address
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What is the purpose of this S-1 filing?
The S-1 filing indicates Shuttle Pharmaceuticals Holdings, Inc.'s intention to offer securities to the public.
When was this S-1 filing submitted?
The S-1 filing was submitted on January 15, 2025.
Where is Shuttle Pharmaceuticals Holdings, Inc. located?
The company's business and mailing address is 401 Professional Drive, Suite 260, Gaithersburg, MD 20879.
What industry does Shuttle Pharmaceuticals Holdings, Inc. operate in?
The company operates in the Pharmaceutical Preparations sector, with a Standard Industrial Classification code of 2834.
What fiscal year-end does the filing reference?
The filing references a fiscal year end of December 31.
Filing Stats: 4,416 words · 18 min read · ~15 pages · Grade level 15.1 · Accepted 2025-01-15 06:37:06
Key Financial Figures
- $831,579 — 4,268 shares of common stock underlying $831,579 in convertible notes (the "Convertible
- $469,214 — ive up to an aggregate of approximately $469,214 from the exercise of all Warrants, assu
- $1.42 — ll for a weighted-average cash price of $1.42 per share of common stock, assuming no
- $0.8999 — rted sale price of our common stock was $0.8999 per share. An investment in our commo
- $0.00001 — nding shares of common stock, par value $0.00001 per share (the "2024 Reverse Stock Spli
Filing Documents
- forms-1.htm (S-1) — 3808KB
- ex5-1.htm (EX-5.1) — 12KB
- ex23-1.htm (EX-23.1) — 4KB
- ex107.htm (EX-FILING FEES) — 49KB
- forms-1_001.jpg (GRAPHIC) — 30KB
- forms-1_002.jpg (GRAPHIC) — 87KB
- forms-1_003.jpg (GRAPHIC) — 38KB
- forms-1_004.jpg (GRAPHIC) — 136KB
- forms-1_005.jpg (GRAPHIC) — 39KB
- forms-1_006.jpg (GRAPHIC) — 40KB
- forms-1_007.jpg (GRAPHIC) — 36KB
- forms-1_008.jpg (GRAPHIC) — 46KB
- forms-1_009.jpg (GRAPHIC) — 11KB
- forms-1_010.jpg (GRAPHIC) — 21KB
- forms-1_011.jpg (GRAPHIC) — 99KB
- ex5-1_001.jpg (GRAPHIC) — 14KB
- 0001493152-25-002253.txt ( ) — 17065KB
- shph-20240930.xsd (EX-101.SCH) — 79KB
- shph-20240930_cal.xml (EX-101.CAL) — 81KB
- shph-20240930_def.xml (EX-101.DEF) — 498KB
- shph-20240930_lab.xml (EX-101.LAB) — 658KB
- shph-20240930_pre.xml (EX-101.PRE) — 574KB
- forms-1_htm.xml (XML) — 2718KB
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 68 MANAGEMENT 80
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 89 BENEFICIAL OWNERSHIP OF SECURITIES 92 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 93 DIVIDEND POLICY 95 DESCRIPTION OF CAPITAL STOCK 95 SHARES ELIGIBLE FOR FUTURE SALE 100 LEGAL MATTERS 101 EXPERTS 101 WHERE YOU CAN FIND MORE INFORMATION 101 DISCLOSURE OF SEC POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES 101 INDEX TO FINANCIAL STATEMENTS F-1 i ABOUT THIS PROSPECTUS The information in this prospectus is accurate only as of the date on the front cover of this prospectus, regardless of the time of delivery of this prospectus or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. You should also read and consider the information in the documents to which we have referred you under the caption "Where You Can Find More Information" in this prospectus. For investors outside the United States: We have not done anything that would permit a public offering of the securities or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities and the distribution of this prospectus outside of the United States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus outside of the United States. You should rely only on the information contained in or incorporated by reference in this prospectus and in any free writing prospectus prepared by or on behalf of us. We have not authorized anyone to provide you with information different from, or in addition to, that contained in or incorporated by reference in this prospectus or any related free writing prospectus. This pros